CANCER REPORTING IN CALIFORNIA:
ABSTRACTING AND CODING PROCEDURES
California Cancer Reporting System Standards, Volume I

Changes and Clarifications – 16th Edition
October 12, 2016

Updates to Volume I - Release #2

GENERAL CHANGES

All Pages:
✓ Per Standard Setters terminology change, most references to “Hospital” throughout Volume I have been updated to “Reporting Facility” or “Facility” and references to “Physician” have been updated to “Provider.”

Select Pages:
✓ Updated Volume I page number links to page name links in the revised pages listed below.

SECTION CHANGES

I.1.6.5 Coding Resources
✓ Updated release dates of the Abstracting and Coding Manuals.
✓ Updated link to PAQC Inquiry System.

II.1 CCR Reportability Guide
✓ Added reportability requirement for cases diagnosed January 1, 2016 forward:
  o Added LIN III (breast lobular intraepithelial neoplasia)
  o Added LN III (breast lobular intraepithelial neoplasia)
✓ Added LI-RADS reportability clarification for Liver.
✓ Added link to Hematopoietic/Lymphoid Coding Manual.
✓ Clarified GIST reportability.
✓ Minor formatting changes.
✓ Corrected typo.

II.2.1 Identifying the Primary Neoplasm and Single or Multiple Tumors
✓ Added clarification for how to code malignancy in a transplanted organ.

II.2.3 Ambiguous Diagnostic Reportable Terms
✓ Added instruction for determining malignancy from all resources.
Add link to Ambiguous Terms for Extent of Disease section.

II.2.5 Hematopoietic and Lymphoid Neoplasm
✓ Amended Hematopoietic and Lymphoid Neoplasm implementation date of the Hematopoietic Database and Manual typo from January 1, 2010 to January 1, 2012.

II.2.5 Address at Diagnosis
✓ Added clarifications to instructions regarding institutionalized patients to include physically handicapped, mentally challenged, mentally ill, long-term residents of care homes, Veterans hospitals etc.

III.2.6 Marital Status
✓ Added Common Law Marriage definition.

III.2.7 Sex
✓ Updated definitions for Intersex and Transsexual.
✓ Added “Transgendered Person” to definition for Transgender.
   o Added coding instruction for Code 3:
     ▪ Intersexed (persons with sex chromosome abnormalities)
     ▪ Hermaphrodite
✓ Updated descriptions for codes 3, 4, 5 to include: Intersex, Transsexual, Transgender, Transgendered.
✓ Added instruction for CCR requirement of text documentation to support the sex field code.

III.2.9 Race and Ethnicity
✓ Corrected typos.

III.2.11 Age at Diagnosis
✓ Added instruction to document patient’s age in the Text Remarks Field when the patient is 100 years or older.

III.3.1 Date of First Contact
✓ Added instruction and example for regarding what to do with date of first contact when the case has been changed from a non-analytic to an analytic.
   o Added example.
✓ Provided link to the Class of Case section of Volume I.

III.3.5 Class of Case
✓ Added instruction and example for regarding what to do with date of first contact when the case has been changed from a non-analytic to an analytic.
   o Added example.
✓ Provided link to the current FORDS Manual.

III.3.14 Comorbidities and Complications
✓ Corrected typo.
V.1 Primary Site

✓ Removed multiple examples of how to code subsite.
✓ Added clarification for how to code primary site of a transplanted organ.
  o Added link to Determining Multiple Primary’s section.
  o Added link to the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database.
✓ Provided instructions for how to code a primary site when there is not enough information in the medical record.
  o Provided link to the Unknown Primary Q-Tip due for release 10/31/16
✓ In reference to the instruction: In the absence of any additional information, assign the codes listed for these primary sites (last instruction).
  o The following codes have been added to the table:
    ▪ Cutaneous leiomyosarcoma C44
    ▪ Glossotonsillary sulcus C109
    ▪ Melanoma, NOS C449
✓ Corrected typo

V.2 Laterality

✓ Clarified that laterality can be coded for non-paired sites.
✓ Added instruction for when it is appropriate to code 0.
✓ Reworded instruction regarding bilateral metastatic involvement is not to be coded for laterality.
✓ Minor formatting changes.
✓ Added instruction for CCR requirement of text documentation to support the laterality field code.

V.3.4.1 In Situ

✓ Reformatted Intraepithelial Neoplasia section to include site specific variations in alphabetical order.
✓ Added reportability requirement for cases diagnosed January 1, 2016 forward:
  o Added LIN III (breast lobular intraepithelial neoplasia)
  o Added LN III (breast lobular intraepithelial neoplasia)
✓ Removed non-reportability reminder regarding non-reportability of AIN II/III, VIN II/III, and VAIN II-III.

V.4.1.1 Tumor Size - Clinical

✓ NEW Instructions added. This is a NEW SEER owned data item, implemented for cases diagnosed January 1, 2016 and forward. Due to the delayed release of the SEER Program Coding and Staging Manual for 2016, instructions for how to code the data item were delayed from being implemented in Volume I.
✓ Added instruction for CCR requirement of text documentation to support the Tumor Size - Clinical field code.
V.4.1.2 Tumor Size - Pathologic

✓ NEW Instructions added. This is a NEW SEER owned data item, implemented for cases diagnosed January 1, 2016 and forward. Due to the delayed release of the SEER Program Coding and Staging Manual for 2016, instructions for how to code the data item were delayed from being implemented in Volume I.

✓ Added instruction for CCR requirement of text documentation to support the Tumor Size - Pathologic field code.

V.4.1.3 Tumor Size - Summary

✓ Clarification made to use the tumor size measurement from the surgical resection specimen, when no pre-surgical treatment is administered.

  o Instruction added to disregard microscopic residual or positive surgical margins when coding tumor size. The status of primary tumor margins may be recorded in a separate data field.

✓ Added instruction for CCR requirement of text documentation to support the Tumor Size - Summary field code.

✓ Minor formatting and typo fixes.

V.4.2 Mets at Diagnosis – Bone, Brain, Distant LNs, Liver, Lung, and Other

✓ NEW Instructions added. This is a NEW SEER owned data item, implemented for cases diagnosed January 1, 2016 and forward. Due to the delayed release of the SEER Program Coding and Staging Manual for 2016, instructions for how to code the data item were delayed from being implemented in Volume I.

✓ Minor formatting changes.

V.4.4 Collaborative Stage Data Collection System

✓ Minor formatting changes.

V.5.1 Stage at Diagnosis

✓ Corrected typo.

V.5.2 Terms Indicating In situ

✓ Reformatted Intraepithelial Neoplasia section to include site specific variations in alphabetical order.

✓ Added reportability requirement for cases diagnosed January 1, 2016 forward:

  o Added LIN III (breast lobular intraepithelial neoplasia)
  o Added LN III (breast lobular intraepithelial neoplasia)

✓ Removed non-reportability reminder regarding non-reportability of AIN II/III, VIN II/III, and VAIN II-III.

V.5.3 Ambiguous Terms for Extent of Disease

✓ Added the following paragraph after the description of ambiguous terms for extent of disease:

  As a general rule, the first and foremost resource for a registrar for questionable cases would be to contact the provider who diagnosed and/or staged the tumor. If the provider is not available, the medical record and any other pertinent reports should be read closely to determine required information. The Ambiguous Terminology list in FORDS and the SEER Summary Stage 2000 manual should be used as a guideline for cases where the wording in the patient record is ambiguous with respect to reportability or tumor spread and there is NO further information available from any
source. Do not refer to the Ambiguous Terminology list(s) when there is a clear statement of malignancy or tumor spread. Registrars should only rely on Ambiguous Terminology lists when the information is not clear and the case cannot be discussed with the appropriate provider/pathologist.

✓ Added sub-heading for AJCC TNM Stage with reference link to AJCC.
✓ Added sub-heading for Commission on Cancer (CoC) with reference link to the FORDS Manual. 
✓ Removed bullet referring abstractor to Collaborative Stage Manual. CS is no longer required for 2016 forward.

V.5.5 SEER Summary Stage

✓ Added link to CCR Website for SEER Summary Stage Presentation, Summary Stage Is Back
✓ Corrected typo.

V.6 AJCC Staging

✓ Added instructions regarding how to TNM Stage when the managing provider has not recorded the stage.
✓ Added instruction regarding AJCC staging used for pediatric cases.
✓ Added instruction for what to do if a site/histology combination is not defined in the AJCC Manual.
✓ Minor formatting changes.

V.6.2 Clinical Staging

✓ Added a list of tests that are considered part of clinical workup.

V.6.2.4 Clinical Stage Group

✓ Added instructions to clarify what to do when the only information available is Stage Group.
  o Example added.

V.6.2.5 Clinical Stage Descriptor - Prefix/Suffix

✓ Corrected typo.

V.6.3 Pathologic Staging

✓ Update page to include list of tests used in Pathologic staging.

V.6.3.4 Pathologic Stage Group

✓ Added instructions to clarify what to do when the only information available is Stage Group.

V.6.3.5 Pathologic Stage Descriptor - Prefix/Suffix

✓ Corrected typo.

V.6.4 AJCC TNM Edition Number

✓ Corrected typo.

VI.2.1 Surgery of Primary Site

✓ Added additional clarification as to when to consider a biopsy excisional.
✓ Added instructions for what to do if a procedure is aborted.
✓ Minor formatting changes.
VI.2.2 Scope Regional Lymph Node Surgery

✓ Added reference to the AJCC Manual in description of data item.
✓ Code 9 of second table titled: The codes for Scope of Regional LN’s are as follows:
  o Added “leukemia/lymphoma histologies”
✓ Minor formatting changes.

VI.2.4 Surgical Procedure of Other Site

✓ Moved priority order instruction above instructions for Code 1.
✓ Revised Code 1 instructions regarding ill-defined primary sites to not include site codes and histologies.
✓ Added code specific instructions for codes 2 and 4.
✓ Moderate formatting changes.

VI.2.7 Surgical Margins of the Primary Site

✓ Added instructions for Codes 1, 2, and 3.
✓ Revised lymphoma instruction to include the term “lymphoid neoplasms” and removed site/histology codes from instruction.
✓ Revised Hematopoietic, Reticuloendothelial, Immunoproliferative, or Myeloproliferative disease instruction to remove site/histology codes from instruction.
✓ Corrected typo.

VI.7 Date of Transplant/Endocrine Procedure

✓ Code 12 - Added syngeneic bone marrow transplant (identical twin) to table.

VI.8.1 Date of Other Therapy

✓ Code 6 - Added cancer therapy administered by non-medical professional to table.

IX.1 Transmission

✓ Removed requirement of encrypted and password protected from first bullet
✓ Replaced Corrections and Follow Up information with Modified Record: Includes any changes to the abstract submitted.
✓ Added note regarding direct transmission of abstracts to the Central Registry.

Terms and Definitions

✓ Added the following definitions:
  o Allograft/Homograft
  o Autograft
  o Common Law Marriage
  o Hematopoietic Growth factors
  o Intersex
  o Non-Myeloablative Therapy
  o Peripheral Blood Stem Cell Transplantation (PBSCT)
  o Rescue
Stem Cells
Stem Cell Transplant
Suspicious Cytology
Targeted Therapy
Transgender
Transgendered Person
Transsexual
Umbilical Cord Stem Cell Transplant

Combined definitions for the following terms as their definitions are the same:
Active Surveillance/Deferred Therapy/Expectant Management/Watchful Waiting

Revised the following definitions for clarity:
Bone marrow Transplant (BMT)
Added intersex, transgender, transgendered, palliative treatment re-wording, targeted therapy, hematologic and endocrine definitions
Palliative Treatment
Microinvasion – added sub-bullet for:
- Microinvasive definition
Tumor Embolization with sub-bullets for:
- Chemoembolization
- Radioembolization

Deleted the following term as it was duplicated in the page:
Conditioning

CHANGES to APPENDICES

Appendix D.1: Codes for Countries in Alphabetical Order

Re-ordered location of terms
- Removed “Dutch East Indies” from table line (Indonesia)
- Removed “Vatican City” from table line (Italy)
- Added table line for Maldives
- Removed “Maldives” from Mid-East Asia NOA table line
- Removed “Ulster” from Northern Ireland table line
- Removed “Trust Territory of Pacific Islands” from Palau table line
- Removed “Territory Occupied” from Palestine table line
- Added table line for Sri Lanka
- Removed “New Zealand” from Tokelau Islands table line
- Added table line for U.S. Minor Outlying Islands

Historical Terms Table – Removed the following terms:
- Czechoslovakia (former) XCZ
- Yugoslavia (former) XYG

NOTE: New codes for these countries were added into Volume I in March 2015 and are in the current codes table. All former codes have been converted to the new code.

Corrected Typo
Appendix D.2: Codes for Countries in Numeric Order

- Re-ordered location of terms.
  - Removed “Dutch East Indies” from table line (Indonesia)
  - Removed “Vatican City” from table line (Italy)
  - Added table line for Maldives
  - Removed “Maldives” from Mid-East Asia NOA table line
  - Removed “Ulster” from Northern Ireland table line
  - Removed “Trust Territory of Pacific Islands” from Palau table line
  - Removed “Territory Occupied” from Palestine table line
  - Added table line for Sri Lanka
  - Removed “New Zealand” from Tokelau Islands table line
  - Added table line for U.S. Minor Outlying Islands

- Historical Terms Table – Removed the following terms:
  - Czechoslovakia (former) XCZ
  - Yugoslavia (former) XYG

  NOTE: New codes for these countries were added into Volume I in March 2015 and are in the current codes table. All former codes have been converted to the new code.

- Corrected Typo

Appendix F: California Reporting Facility Codes

- Updated with current California Reporting Facility Code Numbers.

Appendix Q.2 Skin

- Added link to new page: Q.2.1 Skin, Coding Guidelines

Appendix Q.2.1 Skin – New page

- This page has been introduced to help guide registrars as to how to code multiple surgical procedures for melanoma of the skin.
- The DSQC Memo #2005-04, has been incorporated into this page.

Appendix W.1 Race and Nationality Descriptions

- Code 01 White, added “Creole*”
- Code 01 White, removed duplication of “Moroccan*”
- Corrected typo.

Appendix W.2 Race and Nationality Descriptions

- Added “Creole*”, code 01 – White
- Corrected typo.